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domain	 receptor-2	 (DDR2)	mutation	with	 an	 ongoing	 long-term	 survival	more	 than	 11	 years	
achieved	 with	 surgery,	 chemotherapy	 and	 mitotane	 retreatments.	 To	 date,	 only	 eight	 case	
reports,	 one	 small	 case	 series	 of	 six	 patients	 and	 12	 patients	 from	multicenter	 retrospective	
analysis	 in	 the	 literature	 have	 reported	 on	 patients	 with	 ACC	 who	 have	 achieved	 long-term	
survival	of	more	than	10	years	[5-14].	The	5-year	and	10-year	survival	of	patients	with	metastatic	


















In	 January	 2013,	 He	 underwent	 a	 retroperitoneal	 lymph	 node	 dissection	 and	 left	 partial	






evidence	 of	 progression	 or	 new	 metastases.	 He	 progressed	 with	 numerous	 bilateral	 small	
















although	 some	patients	may	benefit	 from	 surgical	 resection	of	 a	disease	 that	 is	 anatomically	
confined.	The	overall	survival	of	EDP	plus	Mitotane	is	about	14	months	[15].	Mitotane	is	currently	
a	 cornerstone	 in	 the	management	of	 cortisol	 secreting	ACC	 inducing	adrenal	 cortex	necrosis,	
mitochondrial	 membrane	 impairment,	 and	 irreversible	 binding	 to	 CYP	 proteins	 including	
CYP11A1,	 CYP11B1,	 CYP11B2,	 and	 3b-hydroxysteroid-dehydrogenase	 [16,	 17].	 However,	 the	
degree	 of	 response	 to	 mitotane	 is	 variable	 among	 patients	 due	 to	 the	 complexity	 of	 its	
mechanisms	 of	 action,	 pharmacokinetics	 and	 tolerability.	 The	 course	 of	 this	 patient	 was	
remarkable	 because	 he	 achieved	 an	 ongoing	 long-term	 survival	 with	 metastatic	 ACC	 after	










the	 lung	 [23].	 Based	 on	 the	 results	 from	 the	 patient	 tumor	 whole	 genome	 sequencing	 we	
hypothesize,	that	treatment	with	dasatinib	could	be	a	meaningful	approach	 in	case	of	further	
progression	of	the	disease.		
Whole	 genome	 sequencing	 can	 identify	 tumor	 drivers	 and	 potential	 actionable	 mutations,	
generally	brings	detailed	information	on	tumor	heterogeneity	and	guides	clinicians	in	decisions	
making	 for	 treatment	 recommendations	 in	 advanced	 cancers.	 We	 suggest	 whole	 genome	






This	 case	 report	 demonstrates	 an	 exceptionally	 rare	 long-term	 survival	 of	 a	 patient	 with	
metastatic	ACC.	His	 survival	 exceeding	11	 years	was	 achieved	by	 chemotherapy,	 surgery	 and	


































































Figure 1. Treatment outcome in a patient with metastatic ACC treated with 
surgery, chemotherapy and mitotane.  
  
	
Figure legend: (A) left adrenal mass abutting the left kidney and spleen before 
surgery. (B) liver metastases before chemotherapy and mitotane treatment. (C) 
No evidence of Liver metastases on follow-up Computed tomography scan.  
	
